Daniel L. Simmons is a professor of chemistry and former director of the Cancer Research Center at Brigham Young University (BYU).
He was the discoverer of the COX-2 enzyme that is the target of celecoxib (Celebrex) and other COX-2 inhibitors.
In 2014, the Cancer Research Center at Brigham Young University was renamed The Simmons Center for Cancer Research in his honor after he stepped down as director after 17 years.
Simmons has bachelor's and master's degrees from BYU.
From 1986-1989 he held a post-doctoral Fellowship at Harvard University.